Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
- Associated Therapies
- -
A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1549
- Registration Number
- NCT00649090
- Locations
- 🇧🇪
Pfizer Investigational Site, Yvoir, Belgium
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 4
- Registration Number
- NCT00573755
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Gruppo Italiano Mammella (GIM)
- Target Recruit Count
- 3697
- Registration Number
- NCT00541086
- Locations
- 🇮🇹
Federico II University Medical School, Naples, Italy
🇮🇹Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy
🇮🇹Seconda Universita di Napoli, Naples, Italy
Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2011-06-30
- Lead Sponsor
- ARCAGY/ GINECO GROUP
- Target Recruit Count
- 157
- Registration Number
- NCT00525096
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 189
- Registration Number
- NCT00432172
- Locations
- 🇪🇸
Onkologikoa, Donostia, Gipuzkoa, Spain
🇪🇸Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain
🇪🇸Centro Oncológico Regional de Galicia, A Coruña, Spain
A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2010-09-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT00417885
- Locations
- 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 219
- Registration Number
- NCT00372996
- Locations
- 🇦🇷
Instituto de Investigaciones Clinicas, Rosario, Santa Fe, Argentina
🇧🇪UZ Gasthuisberg, Medische Oncologie, Leuven, Belgium
🇦🇷Centro Oncologico Rosario, Rosario, Santa Fe, Argentina
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
- Conditions
- Interventions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10273
- Registration Number
- NCT00310180
- Locations
- 🇺🇸
Saint Ann's Hospital, Westerville, Ohio, United States
🇨🇦McGill University Department of Oncology, Montreal, Quebec, Canada
🇨🇦CHUM-Hotel Dieu de Montreal, Montreal, Quebec, Canada
Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2011-12-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9779
- Registration Number
- NCT00279448
- Locations
- 🇫🇷
Pfizer Investigational Site, Vannes, France
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 622
- Registration Number
- NCT00265759
- Locations
- 🇺🇸
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States
🇺🇸Doctor's Hospital of Laredo, Laredo, Texas, United States
🇺🇸M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.